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ABSTRACT
Background: Chronic hepatitis C is more aggressive during HIV infection. Available 
data about risk factors of liver fibrosis in HIV/HCV co-infected patients derive from 
studies based on a single liver biopsy.
Objectives: To evaluate the risk factors of liver fibrosis progression (LFP) and to inves-
tigate the role of antiretroviral therapy (ARV) in HIV/HCV patients who underwent 
paired liver biopsy.
Patients and Methods: We retrospectively studied 58 patients followed at two Infectious 
Diseases Departments in Northern Italy during the period 1988–2005. All specimens 
were double-blinded and centrally examined by two pathologists. LFP was defined 
when an increase of at least one stage occurred in the second biopsy, according to the 
Ishak-Knodell classification.
Results: In a univariate analysis, serum levels of alanine aminotransferase (ALT) > 150 
IU/L at the first biopsy (P = 0.02), and a > 20% decrease in CD4+ cell count between the 
two biopsies (P = 0.007), were significantly associated with LFP. In multivariate anal-
ysis, a > 20% decrease in CD4+ cell count remained independently associated to LFP 
(odds ratio, 3.99; 95% confidence interval, 1.25–12.76; P < 0.02). Analysis of life survival 
curves confirmed the correlation between CD4+ cell count and LFP.
Conclusions: Our findings highlight that in HIV/HCV coinfected patients, an effective 
antiretroviral therapy that assures a good immune-virological profile contributes to 
reducing the risk of LFP.
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1. Background
The use of highly active antiretroviral therapy (HAART) 
has  significantly  improved  the  life  expectancy  of  HIV-
infected patients mostly due to a drop in opportunistic 
infections, while on the other hand the mortality rate 
due  to  liver  disease  has  dramatically  increased  (1-5). Hepat Mon. 2011;11(7):525-531
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Due to the similar routes of transmission of HCV and 
HIV,  the  prevalence  of  HCV  infection  in  HIV-positive 
patients ranges from 30 to 50%, and can reach up to 90% 
among injecting drug users (6-9). Several studies have 
shown that HIV/HCV co-infected patients show a more 
rapid  progression  to  cirrhosis  (10-12).  Different  factors 
contribute to the accelerated evolution of liver disease; 
central among these is HIV-induced immunosuppression. 
The effect of HAART on liver fibrosis remains controversial. 
Recent data have demonstrated that HAART is associated 
with a reduction of liver-related mortality in HIV/HCV 
co-infected patients (13, 14). A few retrospective studies 
have  reported  a  relationship  between  regimens  of 
antiretroviral  therapy  containing  protease  inhibitors 
(PI),  and  slower  fibrosis  progression  (15-17).  However, 
several studies revealed no association between HAART 
and liver fibrosis progression (18-21). Available data on 
risk  factors  for  liver  fibrosis  progression  in  HIV/HCV 
co-infected  patients  derive  mostly  from  retrospective 
studies based on a single liver biopsy and an estimated 
duration of HCV infection, which make the assumptions 
that the reported date of infection was reliable and that 
liver  fibrosis  progressed  at  a  linear  rate.  Considering 
these limitations, we carried out a study to analyze liver 
fibrosis progression in HIV/HCV co-infected patients who 
underwent paired liver biopsies. 
2. Objectives
The first end point of this study was to evaluate liver 
fibrosis progression (LFP) and its associated risk factors. 
LFP was defined as an increase of at least one stage at 
the  second  biopsy.  The  fibrosis  progression  rate  (FPR) 
was  defined  as  the  difference  between  scores  at  two 
consecutive biopsies divided by the time in years elapsed 
between these two biopsies. The second end point was 
a IQR: Interquartile range, b IDU: Injecting drug use, c CDC: Centers for Disease Control and Prevention, d ART: Antiretroviral therapy, e HAART: Highly active anti-
retroviral therapy, f ALT: Alanine aminotransferase, g CI: Confidence interval
Characteristics
Sex (Male), No. (%) 43 (74)
Age, y (IQR a)  34 (22-39.5) 
Risk category, No. (%)
IDU b
Sexual contact
49 (84)
9 (16)
CDC c stage, No. (%)
A
B
C
25 (43)
17 (29)
16 (28)
ART d received, No. (%)
None
Single or dual
HAART e
20 (34.5)
27 (46.5)
11 (19)
CD4+ T cells count at 
   Liver biopsy, cells/mmc (IQR)
    Nadir, cells/mmc (IQR)
449.5 (308-676)
194 (97-290)
HCV genotype, No. (%)
1
2
3
4
Not available
18 (31,1)
1 (1,7)
21 (36,2)
4 (6,9)
14 (24,1)
Staging, No. (%)
0-1
2
3
4
28(48.2)
17(29.3)
10(17.2)
2 (3.3)
History of alcohol abuse, No. (%)
ALT f at liver biopsy, IU/l (IQR)
Grading mean 95% CI g
21 (36)
114 (72-163)
4 (3.4-4.5)
Staging mean 95% CI 1.67 (1.37-1.97)
Table 1. Characteristics of the patients at first liver biopsyHepat Mon. 2011;11(7):525-531
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to  evaluate  the  effect  of  antiretroviral  therapy  on  the 
progression of liver fibrosis.
3. Patients and Methods
We  retrospectively  studied  HIV/HCV  patients  who 
underwent  paired  liver  biopsies  during  the  period 
1988–2005.  Patients  enrolled  were  addressed  at  the  II 
Department of Infectious Diseases of L. Sacco Hospital 
and  at  the  Division  of  Infectious  Diseases,  S.  Raffaele 
Scientific Institute, Milan, Italy. HCV infection was defined 
by a positive serology result after a second-generation 
enzyme-linked  immunosorbent  assay  (ELISA),  and 
positivity for plasma HCV-RNA through a branched-DNA 
PCR  assay  (Bayer).  Only  patients  who  underwent  two 
sequential  liver  biopsies  with  an  adequate  sample  for 
histological analysis and who had available clinical data 
were included in the study.
3.1. Patient evaluation
For each patient a case report was recorded, including 
epidemiological  and  clinical  features  [sex,  age,  risk 
factors for HIV infection, HIV stage (according to 1992 
revised  Centers  for  Disease  Control  and  Prevention 
(CDC) classification), and history of high alcohol intake 
(defined as a consumption of > 50 g of alcohol per day)], 
biochemical data [levels of aspartate aminotransferase 
(AST)  and  alanine  aminotransferase  (ALT)],  immune 
profile (CD4+ cell count), and HIV RNA level (available 
from 1996), recorded at the time of the first liver biopsy 
and  subsequently  every  year  until  the  second  biopsy. 
The study was conducted with local Ethical Committee 
approval and all patients signed specific consent forms.
3.2. Histological evaluation
Percutaneous  liver  biopsies  were  performed  using 
Menghini’s needle to obtain specimens > 10 mm long, 
which  were  fixed  in  10%  formalin  buffer  and  stained 
with hematoxylin-eosin. The threshold of adequacy for 
histological assessment was the presence of more than 
10 portal tracts. All specimens were double-blinded and 
centrally  examined  by  two  experienced  pathologists, 
who were not aware of the clinical and biological data 
of the patients. The Knodell score system, modified by 
Ishak (1995, revised in 2000) (22, 23), was used to assess 
necroinflammatory activity and fibrosis. Patients at stage 
5–6 during the baseline liver biopsy were excluded.
3.3. Statistical analysis
Software packages Graph Pad Prism (version 3.02) for 
Windows, Graph Pad Instat (version 3.05) for Windows 95 
(Graph Pad Software, San Diego, CA, USA, www.graphpad.
com), and Stata 7.0 (Stata Corporation – Lakeway Drive 
College  Station,  Texas  USA,  www.stata.com)  were  used. 
Descriptive  statistics  were  expressed  as  medians  and 
Interquartile Ranges (IQR) or mean and 95% Confidence 
Interval (95% CI), and as percentage, for continuous and 
categorical variables, respectively. Continuous variables 
were compared using the nonparametric Mann-Whitney 
test and the unpaired t test when appropriate. Differences 
in proportions were performed using Fisher’s exact test. 
Investigated  risk  factors  for  LFP  included:  age  at  liver 
biopsy, gender, risk factors for HIV transmission, clinical 
stage of the disease, baseline and nadir CD4+ cell counts, 
HIV RNA at baseline, modifications of CD4+ cell counts 
and HIV RNA (when available) between two consecutive 
biopsies, ALT levels, HCV genotype, daily alcohol intake, 
antiretroviral  therapy,  and  histological  grading  of 
activity  (according  to  the  Knodell-Ishak  score).  For 
each parameter, univariate logistic regression analysis 
was performed to calculate odds ratio (OR) and 95% CI 
for  fibrosis  progression  versus  non-progression.  Only 
significant variables in univariate analysis were included 
in multivariate analysis by means of logistic regression. 
The Kaplan-Meir plot (log rank test) was used to identify 
differences in time for LFP in relation to the trends of 
CD4+ cell count between the two biopsies and to the use 
of HAART.
4. Results
4.1. Study population
During  the  study  period,  65  HIV/HCV  co-infected 
patients  with  paired  liver  biopsies  were  considered. 
Among them, 58 patients met the inclusion criteria. The 
main characteristics of the patients at the first biopsy 
are shown in Table 1. The mean time between the two 
biopsies was 42.64 months (95% CI 33.7–51.5). Most of the 
patients  were  male,  with  median  age  of  34  years.  The 
median of the CD4+ cell count was high (> 400/mm3). 
6 out of 58 patients (10.3%) had CD4+ cells count < 200/
mm3 at baseline and 33 (56.8%) had CD4+ cell count < 200 
cells/mm3 at nadir. The median ALT value was 114 IU/L; 
17 out of 58 patients (29.3%) had ALT values > 150 IU/L. 
Most of the patients had a baseline stage of ≥ 2 (51.7%). 
At baseline, 20 patients (34.5%) received no antiretroviral 
therapy, 27 patients (46.5%) received monotherapy or a 
combination  of  two  nucleoside  reverse  transcriptase 
inhibitors (NRTIs) and 11 patients (19%) received HAART. 
In the period between the two biopsies, six patients (10%) 
remained  naive  to  antiretroviral  therapy,  32  patients 
(55%)  received  monotherapy  or  a  combination  of  two 
NRTIs, and 20 patients (35%) received HAART. Forty out 
of 58 (69%) patients were treated with interferon therapy 
after the first biopsy. All patients were non-responders or 
prematurely discontinued anti-HCV treatment.
4.2. Liver fibrosis progression
LFP  was  observed  in  27  patients  (46.5%).  9  out  of  58 
patients (15.5%) showed an increase of more than two 
fibrosis stages in the second biopsy. Five out of 58 patients 
(8.6%) developed cirrhosis. The mean time between the Hepat Mon. 2011;11(7):525-531
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two biopsies was comparable in the two groups: 38.69 
months (95% CI 28.2–49.0) in patients who progressed 
versus  45.9  months  (95%  CI  31.6–60.2)  in  patients  who 
did not (P = 0.93 Mann Whitney test). A comparison of 
patients who progressed and those who did not showed 
a significant difference in mean stage score at the first 
biopsy (1.3 ± 0.9 vs. 1.96 ± 1.22, P = 0.03; unpaired t test) 
and in mean ALT values at baseline (173.41 ± 26.52 IU/L 
vs. 111.55 ± 50.6 IU/L, P = 0.03; unpaired t test with Welch 
correction). Age, grading score, and CD4+ cell counts at 
baseline and at nadir were comparable between the two 
groups. In 25 patients out of 58 (43%) CD4+ cell count 
decreased by more than 20%, and in 22 patients (38%) 
increased by more than 20% between the two biopsies. In 
the group of patients who progressed, CD4+ cell count 
decreased  by  more  than  20%  in  17  out  of  27  patients 
(62.9%).  HIV  RNA  level  data  was  available  for  the  20 
patients who received HAART between the two biopsies. 
HIV  RNA  remained  undetectable  (less  than  the  cutoff 
value) in most of the determinations recorded between 
the two biopsies in only three out of the 10 patients who 
progressed (30%), and in seven out 10 (70%) in the group 
of non-progressors.
4.3. Risk factors for fibrosis progression
We studied the correlation between the LFP and age, 
gender,  route  of  HIV  transmission,  CDC  stage  of  HIV 
infection,  history  of  alcohol  abuse,  ALT  >  150  IU/L  at 
baseline  (>  grade  2,  according  to  ACTG  scale  of  liver 
toxicity), CD4+ cell count < 200/mm3 at nadir and < 350/
mm3  at  first  biopsy,  detectable  HIV  RNA  during  more 
than  50%  of  the  time  period  considered  (available  in 
the patients treated with HAART between two biopsies), 
histological  necroinflammatory  index  (grading),  and 
antiretroviral  therapy.  The  results  of  the  univariate 
analysis are summarized in Table 2. A decrease of > 20% in 
CD4+ cell count between the two biopsies (OR 4.88, 95% 
CI 1.59–15, P = 0.007), and higher ALT values at first biopsy 
(OR  4.16,  95%  CI  1.22–14.1,  P  =  0.02),  were  significantly 
associated with the progression of liver fibrosis. Moreover, 
detectable HIV RNA, high alcohol consumption, and a 
Factors OR a, 95% CI b P value
Age (>35 y at liver biopsy) 0.7 (0.24-2.04) 0.59
Sex (Male)  1.43 (0.43-4.72) 0.7
History of alcohol abuse 2.67 (0.88-8.04) 0.067
ALT c (>150 IU/L at first biopsy) 4.16 (1.22-14.11) 0.02
No interferon treatment 2.35 (0.75-7.36) 0.16
CD4
Nadir (< 200/mmc)
At first biopsy (< 350/mmc)
Between two biopsies (< 200/mmc) 
2.1 (0.73-6.19)
0.69 (0.23-2.02)
3.37 (0.9-12)
0.19
0.59
0.06
No ART d, Single or dual NRTIs e vs. HAART f
At first biopsy
Between two biopsies
0.67 (0.1-2.5)
0.8 (0.2-2.39)
0.73
0.7
Decrease of CD4  (> 20% between two biopsies) 4.88 (1.59-15) 0.007
Detectable HIV RNA 5.44 (0.8-36.8) 0.08
Route of HIV transmission (IDU g vs. other) 1.1 (0.2-4.6) 1
CDC h stage (C vs. A or B) 1.7 (0.5-5.4) 0.3
Table 2. Univariate analysis of factors associated with  liver fibrosis progression
a OR: Odds ratio 
b CI: Confidence interval
c ALT: Alanine aminotransferase
d ART: Antiretroviral therapy
e NRTIs: Nucleoside reverse transcriptase inhibitors
f HAART: Highly active antiretroviral therapy
g IDU: Injecting drug use
h CDC: Centres for Disease Control and Prevention
 
 Factors OR a IL, 95% CI SL, 95% CI b P value
CD4+ decrease (> 20%) 3.99 1.25 12.76 0.020
ALT c (> 150 IU/L) 3.10 0.85 11.31 0.087
Table 3. Multivariate analysis (logistic regression) of factors associated with liver fibrosis progression (staging increase of one)
a OR: Adjusted odds ratio
b CI: Confidence interval 
c ALT: Alanine aminotransferase Hepat Mon. 2011;11(7):525-531
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drop of CD4+ cell count to < 200/mm3 between the two 
biopsies were also related to a high risk of progression 
even if they did not reach statistical significance.
No significant correlation was found between LFP and 
the presence of antiretroviral therapy at the first biopsy 
and also between the two biopsies. In the multivariate 
analysis, a decrease in CD4+ cell count between the two 
biopsies  remained  independently  associated  with  LFP 
(Table 3). Analysis of life survival curves confirmed that 
an increase in CD4+ cell count between the two biopsies 
was significantly correlated with slower LFP (Figure 1). We 
determined the liver fibrosis progression rate per years 
(FPR)  in  the  27  patients  who  progressed:  the  median 
FPR  was  0.51  (IQR  0.31–0.64).  At  this  rate  of  fibrosis 
progression, the median expected time to cirrhosis was 
11.7 years (IQR 9.3–19.3).
5. Discussion
A more rapid progression of liver disease in HIV/HCV co-
infected patients is well documented in a large number 
of studies (10-12, 24). However, the majority of available 
studies on liver fibrosis progression used a single liver 
biopsy with an estimated duration of HCV infection to 
calculate  FPR  (17-19,  24-26).  The  calculation  of  FPR  has 
been extensively applied but assumes linear progression 
through  all  stages  of  infection.  This  assumption  has 
effectively no clear evidence base. In the current study, 
we  evaluated  LFP  in  patients  who  underwent  two 
consecutive  biopsies.  The  rate  of  progression  of  liver 
fibrosis in our cohort was variable: in fact, we observed 
rapid progression even in patients with a lower stage 
score at baseline (median FPR 0.51/year) with an expected 
time to cirrhosis of less than 12 years, whereas the majority 
of patients (53.5%) did not show progression. Thus, this 
study provides strong evidence that progression of liver 
fibrosis in HIV/HCV co-infected patients is not linear.
In addition, we demonstrated that, even in patients with 
mild liver disease at first biopsy (stage 0–1), progression 
of fibrosis could occur in a significant proportion (27.5%) 
in  <  43  months.  This  is  consistent  with  the  findings 
of  Sulkowski  et  al.  who  demonstrated  that  significant 
fibrosis progression occurred in 24% of 174 non-cirrhotic 
HIV/HCV patients, although no or minimal fibrosis was 
detected in 77% of these patients in the first liver biopsy 
(27). The rate of LFP in HIV/HCV co-infected patients is 
clearly higher than that observed in HCV-monoinfected 
patients, where available data showed rates from 8% to 
12% (28, 29). Different parameters have been previously 
identified as risk factors for severe liver fibrosis in HCV-
positive patient cohorts: increased age, duration of HCV 
infection,  high  alcohol  intake,  high  ALT  serum  levels, 
and high necroinflammatory index (15, 19, 21, 30-36). In 
our study, only high ALT serum levels were significantly 
associated to LFP in a univariate analysis. In the study by 
Sulkowski et al, levels of serum AST also play an important 
role in predicting future liver disease, leading to support 
of the use of this prognostic marker in HCV treatment 
decision algorithms (27).
Other  factors  related  to  HIV  infection  may  be  also 
involved  in  LFP.  Several  studies  have  previously 
demonstrated  that  a  low  CD4+  cell  count  is  strongly 
associated with rapid progression of fibrosis in HIV/HCV 
co-infected patients (15, 21, 36, 37). Immunosuppression 
due  to  HIV  could  induce  modifications  of  cytokine 
patterns in the liver towards a Th2 response, which has 
been  demonstrated  to  be  associated  with  advanced 
fibrosis in animal models (37-39). Regarding the role of 
antiretroviral therapy, in a recent study, Brau et al. (26) 
showed that HIV/HCV co-infected patients with HIV RNA 
< 400 cp/mL exhibited FPR similar to HCV monoinfected 
patients  (0.122/year  vs.  0.128),  whereas  patients  with 
detectable HIV RNA had a higher FPR (0.15/year). In this 
study, HIV RNA, and not CD4+ cell count, was the best 
predictor of liver fibrosis. In another recent study, Verma 
et  al.  (25)  compared  85  HIV/HCV  co-infected  and  296 
HCV-monoinfected patients during a period of 10 years, 
and  demonstrated  that  patients  taking  HAART  as  the 
first antiretroviral regimen had an FPR similar to HCV-
monoinfected subjects; HAART, but not CD4+ cell count or 
HIV RNA level, was independently related to liver fibrosis. 
It is necessary to emphasize that in these studies, a single 
value of CD4+ cell count and HIV RNA, corresponding to 
the date of liver biopsy, were considered in the analysis, 
whereas in our study we evaluated not a single value, but 
the trend of the CD4+ cell count and, when available, HIV 
RNA levels in the period between the two biopsies. In fact, 
we observed that a decrease of more than 20% in CD4+ 
cell count between the two biopsies was independently 
correlated to LFP. Additionally, in 20 patients who were 
taking  HAART,  the  presence  of  detectable  HIV  RNA  in 
more than 50% of determinations was related to a faster 
LFP, although without statistical significance, probably 
due to the small number of patients with available HIV 
RNA. Furthermore, we observed that an increase of more 
than 20% in CD4+ cell count between the two biopsies, 
which can be related to efficient antiretroviral therapy, 
was  also  significantly  related  to  slower  LFP.  However, 
we  demonstrated  no  association  between  LFP  and 
the  absence  or  specific  type  of  antiretroviral  therapy 
(HAART,  combination  of  two  NRTIs,  or  monotherapy), 
underlining that only effective therapy, which results in 
Chi square 5.4  df1   P = 0.01
) )
Figure 1. Analysis of life survival curve showing an increase of CD4 cells 
count between two biopsies and the correlation with slower LFPHepat Mon. 2011;11(7):525-531
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an increase in CD4+ cell count and HIV RNA suppression, 
is really relevant to reduce LFP.
Our  findings  that  ALT  levels  and  a  decrease  in  CD4+ 
cell count, but not other parameters, were significantly 
correlated  to  LFP,  might  be  due  to  the  small  number 
of  enrolled  patients  and  to  the  retrospective  nature 
of  the  analysis;  therefore,  an  increase  in  sample  size 
might provide further information. A recent study on 
paired liver biopsy in HIV/HCV co-infected patients has 
demonstrated the efficacy of PEG-IFN therapy in reducing 
or stabilizing liver fibrosis, in comparison to untreated 
patients, who presented faster progression even in the 
absence of a sustained virological response (40). In our 
study, we did not find a correlation with anti-HCV therapy, 
probably due to the fact that all our patients had been 
treated in the past, mostly with suboptimal schedules 
based on standard IFN monotherapy, or had prematurely 
discontinued treatment.
In  conclusion,  our  data  suggest  that  in  HIV/HCV 
co-infected  patients  the  introduction  of  effective 
antiretroviral  therapy  is  also  relevant  to  reduce  LFP. 
Therefore, significant efforts should be made to obtain 
patients’ adherence to antiretroviral therapy, in order to 
reduce the occurrence of viral resistance and guarantee a 
good immune-virological profile. Thus, early introduction 
of antiretroviral therapy should be considered in HIV/
HCV co-infected patients, especially in the presence of 
contraindications to anti-HCV therapy or in patients that 
were  non-responsive  to  previous  antiviral  treatments. 
The evidence of rapid progression in subjects with mild 
liver disease suggests the need for adequate screening 
and aggressive treatment of HCV infection even in this 
subset of patients.
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